Table 1 Baseline characteristics: participants in the Exacerbations(No recent) populationa
Step up to ICS/LAMA/LABA | Switch to LAMA/LABA | Stay on ICS/LABA | ||
|---|---|---|---|---|
BGF 320/14.4/10 μg (N = 188) | GFF 14.4/10 μg (N = 196) | BFF 320/10 μg (N = 85) | BUD/FORM 400/12 μg (N = 85) | |
Age,b mean years (SD) | 63.7 (7.5) | 63.3 (7.9) | 64.3 (6.7) | 63.6 (7.2) |
Sex, n (%) | ||||
Female | 56 (29.8) | 65 (33.2) | 23 (27.1) | 26 (30.6) |
Male | 132 (70.2) | 131 (66.8) | 62 (72.9) | 59 (69.4) |
Current smoker, n (%) | 84 (44.7) | 93 (47.4) | 34 (40.0) | 39 (45.9) |
Moderate or severe exacerbations in the previous year, n (%) | ||||
None (0) | 188 (100.0) | 196 (100.0) | 85 (100) | 85 (100) |
Exacerbation number (past 12 months), mean (SD) | NA | NA | NA | NA |
Blood eosinophil count > 100 cells/mm3, n (%) | 137 (72.9) | 142 (72.4) | 59 (69.4) | 55 (64.7) |
Blood eosinophil count ≥ 150 cells/mm3, n (%) | 98 (52.1) | 101 (51.5) | 46 (54.1) | 29 (34.1) |
Post-bronchodilator FEV1% predicted, mean (SD) | 51.7 (14.1) | 51.7 (13.9) | 49.6 (11.9) | 51.6 (13.9) |
Reversible to bronchodilator,c n (%) | 91 (48.4) | 97 (49.5) | 42 (49.4) | 40 (47.1) |
Total CAT score, mean (SD) | 19.0 (6.8) | 18.9 (6.5) | 19.5 (7.3) | 19.2 (6.6) |